SomaLogic
SomaLogic's high-throughput proteomics technology uses single-stranded DNA aptamers that bind specific proteins with high specificity and sensitivity.
- Acquired Subsidiary
- Boulder, CO, USUnited States
SomaLogic's high-throughput proteomics technology uses single-stranded DNA aptamers that bind specific proteins with high specificity and sensitivity.
somalogic.comCrawled Nov 3, 2026
You can now access the power of our pioneering 7,000-plex SomaScan Platform at a research institution near you.
The SomaLogic Menu tool allows users to search, filter, and sort SOMAmers and analyte offerings for custom research panels.
SomaLogic’s Certified Site Program includes research facilities partnered with the company.
View and access biobanks from across the world, that are all using the SomaScan Assay
Somascan Discovery Blogs + News
Lab spotlight. Omics-based research yields deeper insight into disease development. How omics-based research improves potential discoveries
Somascan Discovery Posters
Revealing novel biomarkers of Parkinson’s Disease in CSF samples using expansive proteome coverage and high data accuracy of the SomaScan Assay
SomaLogic presents scientific sessions and booth 2917 at the AHA Annual Meeting.
SomaLogic offers research grants for assaying over 7,000 proteins through its Authorized Site partner, Genomax.
The infographic compares Single SOMAmer Reagents and antibodies for affinity assays, highlighting differences in structure, specificity, stability, and scalability.
Explore nearly 11,000 synthetic affinity reagents targeting human proteins. Find reliable, animal free antibody alternatives for ELISA, pull-downs, and more.
SomaLogic is empowering more accurate diagnosis, prevention, and treatment of disease through the next generation of proteomics.
SomaLogic has an extensive intellectual property (IP) estate of issued patents and pending patent applications.
SomaLogic's pioneering SomaScan Platform has transformed life sciences research by providing a single platform for discovery, validation, and development.
The Consortium exists to promote collaboration among prospective cohort studies that follow participants for a range of outcomes and perform SomaScan profiling of individuals.
SomaLogic’s proteomics platform covers more of the proteome than other technologies.
Illumina acquires SomaLogic for $350 million to integrate its scalable proteomics technology into its multiomics platform. The move aims to accelerate drug discovery and enhance precision health care solutions. SomaLogic’s proteomics capabilities complement Illumina’s existing genomic and other molecular profiling tools.
Feb 2026Pharmacally -News article
Illumina acquires SomaLogic’s assets from Standard BioTools in a deal valued at up to **$425 million**. The transaction follows Standard BioTools’ acquisition of SomaLogic—itself a partner of Illumina—less than **18 months ago**. The move consolidates protein-profiling capabilities within Illumina’s portfolio.
Jun 2025genomeweb.comNews article
Standard BioTools completes the sale of its SomaLogic subsidiary to Illumina, generating up to **$425 million** in total proceeds. The deal includes **$350 million in upfront cash** alongside near-term milestone payments. The transaction marks a major step in the company’s strategic restructuring.
Jun 2025Standard BioTools Inc.News article
Illumina acquires SomaLogic in a deal valued at up to **$425 million**. The move expands Illumina’s portfolio in **protein-based biomarker discovery**, complementing its existing genomic sequencing technologies. SomaLogic specializes in **highly multiplexed proteomics**, enabling large-scale protein analysis for research and diagnostics.
Jun 2025Yahoo FinanceNews article